Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Old API Wind-down Ltd - Ordinary Shares ARLZQ

"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently operates in two geographical markets, the United States and Canada. The firm generates most of its reven


OTCPK:ARLZQ - Post by User

Comment by snootchybootchyon Mar 20, 2017 1:19pm
104 Views
Post# 26002899

RE:RE:RE:Picks like ARZ come around very rarely

RE:RE:RE:Picks like ARZ come around very rarely
kuatolives wrote: Insiders can be the most deluded of all investors. Look at Ackman. Also, you have no idea what Adam's personal finances are like. If he's up millions in other investments, buying a chunk of ARLZ presents little risk because he either A) gets the upside in a rebound or B) gets the writeoff if/when he takes the loss.   Yes, it can be a measure of confidence, but I wouldn't put too much on it.

For me, it's just about whether I think I can make more $$ with my capital deployed elsewhere, and I think I can so... that's it. Again, if Q1 numbers suck, that's it for this company. That's mondo risk.


As per Mr. Adams' press release this morning, it sounds like there will be more news that will be released before the Q1 numbers come out.  Could be updated Yosprala sales numbers or perhaps news of an acquisition.  Even some good news about the Teva lawsuit would help burn the shorts a bit.  There is also going to be another article from Mr. Goldman on Seeking Alpha this week, which should help juice the share price a bit.

And nobody throws down over a million dollars on a stock, no matter how flush he is with cash.  And what about all the insiders who invested collectively over $200,000?  Do they all have superfluous cash lying around too? 
<< Previous
Bullboard Posts
Next >>